Combination Regimens May Improve Responses in Ovarian Cancer
Floor J. Backes, MD, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.
Floor J. Backes, MD, an associate professor in the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer CenterJames, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.
There are PD-1/PD-L1 antibodies, as well as antiCTLA-4 antibodies, says Backes. There are also many combinations with these different agents currently in development in clinical trials for ovarian cancer.
Backes notes that the checkpoint inhibitors have not shown very high responses in patients with ovarian cancer. The responses with checkpoint inhibitors have only ranged from 10% to 15%. Because of this, combination regimens are under evaluation to see if we can make these more effective. Investigators are combining immunotherapy with antiangiogenic agents, antiCTLA-4 antibodies, or PARP inhibitors.
With these combinations, it always seems like we can achieve higher responses than we can with the single agents alone, Backes concludes.
<< View more resources and information regarding gynecologic cancers
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
